Cogent BiosciencesCOGT
COGT
About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Employees: 164
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
37% more call options, than puts
Call options by funds: $575K | Put options by funds: $421K
27% more capital invested
Capital invested by funds: $1.04B [Q2] → $1.32B (+$278M) [Q3]
17% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]
10% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 48
9% more funds holding
Funds holding: 148 [Q2] → 161 (+13) [Q3]
17.49% less ownership
Funds ownership: 128.81% [Q2] → 111.32% (-17.49%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
92%
upside
Avg. target
$17
118%
upside
High target
$21
169%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Needham Ami Fadia 32% 1-year accuracy 50 / 154 met price target | 92%upside $15 | Hold Downgraded | 11 Dec 2024 |
JP Morgan Anupam Rama 27% 1-year accuracy 16 / 59 met price target | 169%upside $21 | Overweight Maintained | 14 Nov 2024 |
Citigroup David Lebowitz 41% 1-year accuracy 9 / 22 met price target | 92%upside $15 | Buy Maintained | 24 Sept 2024 |
Financial journalist opinion
Based on 3 articles about COGT published over the past 30 days
Positive
Benzinga
2 weeks ago
Why Is Cogent Biosciences Stock Trading Higher On Monday?
On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis.
Neutral
GlobeNewsWire
2 weeks ago
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS
Neutral
GlobeNewsWire
2 weeks ago
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass.
Positive
Zacks Investment Research
5 months ago
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Neutral
GlobeNewsWire
6 months ago
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
Neutral
GlobeNewsWire
7 months ago
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).
Neutral
GlobeNewsWire
7 months ago
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors (GIST). The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1. Cogent also announced today a new Phase 2 clinical trial of bezuclastinib plus sunitinib in later line GIST patients, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute.
Neutral
GlobeNewsWire
7 months ago
Cogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025
Neutral
PRNewsWire
8 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cogent Biosciences, Inc. (NASDAQ: COGT) on behalf of the company's shareholders. The investigation seeks to determine whether Cogent Biosciences, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Neutral
GlobeNewsWire
8 months ago
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
WALTHAM, Mass. and BOULDER, Colo.
Charts implemented using Lightweight Charts™